Kadimastem Announces Encouraging Results of Cohort B of its Phase 1/2a Clinical Trial of AstroRx® for ALS
USA - English
No treatment-related serious adverse events nor dose-limiting toxicities were reported during the 6- month post-treatment follow up
Clinically meaningful decline in disease progression was observed during the first 3-month of the 6-month follow up period, consistent with the results reported previously for Cohort A
News provided by
Share this article
Share this article
NESS ZIONA, Israel, Dec. 15, 2020 /PRNewswire/ Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company, announced today encouraging results of Cohort B of its Phase 1/2a clinical trial of AstroRx
check it out. here is one way for protesters to get noticed. dress up as your cause. but can you tell what it is? about 200 protesters in paris dressed up as embryos. yeah, that s what that is. they re against a draft law that would allow research own human embryonic stem cells. a parliament vote is expected on tuesday. and it is time now for first buzz. one of my favorite segments of the entire day. and i love this one. i m going to start because it s my favorite. you got to check this out. these babies singing we will rock you. we will, we will rock you we will, we will rock you i was so impressed by the littlest one. seemed to be the one singing the most. i know.
british researchers gave the animals shots of stem cells taken from human embryos. the bbc s fergus walsh shows us how it works. reporter: these nerve cells under the microscope are what researchers hope one day will reverse deafness. they were created from human embryonic stem cells which have the ability to turn into any tissue. the scientists are trying to tackle a form of deafness that affects one in ten people. with profound hearing loss. in the condition, nerve cells in the cochlea, inner ear are damaged preventing sound from traveling along the auditory nerve to the brain. like cutting a telephone wire. in the lab, they grew stem cells, smaller than a pinhead and grew them into healthy replacement nerve cells and injected these into 18 deaf gerbils, considered a good animal model for human hearing. tests showed on average, about 45% of their hearing was restored.
now. let s go to nbc news justice correspondent pete williams with more on that. hey, pete. good day to you. this involves the very controversial issue of research using human embryonic stem cells. last year a federal judge here in washington said the federal government could not use federal money to pay for research using embryonic stem cells and threatened to bring to a halt research that was going on in many clinics and universities around the country. it was considered a victory for opponents and a great defeat for people who think that embryonic stem cells hold promise for a cure for a number of diseases. a federal appeals court overturned that lower court ban by a vote of two to one. a panel lifted the injunction that blocked the federal government from spending any federal money to finance research using human embryonic stem cells. the panel said that the congressional language that the
pleasantly surpriseded they were smiling, these men. they had no life-threatening conditions. they spent more than two months in the conditions that the human body just isn t designed for. it s really hot. it s really humid. it was the overall planning of the rescue and the types of food and medications and hydration these men have been given that made the whole process so successful. it is likely that the focus is going to be on their psychological condition in the weeks to come. they think it s important to provide updates on exactly how they ve been doing. we ve been with the story for a long time. we re not going anywhere. we re going to stay on it. also, another historic moment. 12 years after the first human embryonic stem cells were isolated. the first person has been injected with a product that was derived from human embryonic stem cells. think about that. just this week, the company is not revealing a lot about the patient. he or she was thought to have been paralyzed less